Cargando…

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies

Background: The challenging market access of high-cost one-time curative therapies has inspired the development of alternative reimbursement structures, such as outcome-based spread payments, to mitigate their unaffordability and answer remaining uncertainties. This study aimed to provide a broad ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Michelsen, Sissel, Nachi, Salma, Van Dyck, Walter, Simoens, Steven, Huys, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753155/
https://www.ncbi.nlm.nih.gov/pubmed/33363468
http://dx.doi.org/10.3389/fphar.2020.594446
_version_ 1783626011301117952
author Michelsen, Sissel
Nachi, Salma
Van Dyck, Walter
Simoens, Steven
Huys, Isabelle
author_facet Michelsen, Sissel
Nachi, Salma
Van Dyck, Walter
Simoens, Steven
Huys, Isabelle
author_sort Michelsen, Sissel
collection PubMed
description Background: The challenging market access of high-cost one-time curative therapies has inspired the development of alternative reimbursement structures, such as outcome-based spread payments, to mitigate their unaffordability and answer remaining uncertainties. This study aimed to provide a broad overview of barriers and possible opportunities for the practical implementation of outcome-based spread payments for the reimbursement of one-shot therapies in European healthcare systems. Methods: A systematic literature review was performed investigating published literature and publicly available documents to identify barriers and implementation opportunities for both spreading payments and for implementing outcome-based agreements. Data was analyzed via qualitative content analysis by extracting data with a reporting template. Results: A total of 1,503 publications were screened and 174 were included. Main identified barriers for the implementation of spread payments are reaching an agreement on financial terms while considering 12-months budget cycles and the possible violation of corresponding international accounting rules. Furthermore, outcome correction of payments is currently hindered by the need for additional data collection, the lack of clear governance structures and the resulting administrative burden and cost. The use of spread payments adjusted by population- or individual-level data collected within automated registries and overseen by a governance committee and external advisory board may alleviate several barriers and may support the reimbursement of highly innovative therapies. Conclusion: High-cost advanced therapy medicinal products pose a substantial affordability challenge on healthcare systems worldwide. Outcome-based spread payments may mitigate the initial budget impact and alleviate existing uncertainties; however, their effective implementation still faces several barriers and will be facilitated by realizing the required organizational changes.
format Online
Article
Text
id pubmed-7753155
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77531552020-12-23 Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies Michelsen, Sissel Nachi, Salma Van Dyck, Walter Simoens, Steven Huys, Isabelle Front Pharmacol Pharmacology Background: The challenging market access of high-cost one-time curative therapies has inspired the development of alternative reimbursement structures, such as outcome-based spread payments, to mitigate their unaffordability and answer remaining uncertainties. This study aimed to provide a broad overview of barriers and possible opportunities for the practical implementation of outcome-based spread payments for the reimbursement of one-shot therapies in European healthcare systems. Methods: A systematic literature review was performed investigating published literature and publicly available documents to identify barriers and implementation opportunities for both spreading payments and for implementing outcome-based agreements. Data was analyzed via qualitative content analysis by extracting data with a reporting template. Results: A total of 1,503 publications were screened and 174 were included. Main identified barriers for the implementation of spread payments are reaching an agreement on financial terms while considering 12-months budget cycles and the possible violation of corresponding international accounting rules. Furthermore, outcome correction of payments is currently hindered by the need for additional data collection, the lack of clear governance structures and the resulting administrative burden and cost. The use of spread payments adjusted by population- or individual-level data collected within automated registries and overseen by a governance committee and external advisory board may alleviate several barriers and may support the reimbursement of highly innovative therapies. Conclusion: High-cost advanced therapy medicinal products pose a substantial affordability challenge on healthcare systems worldwide. Outcome-based spread payments may mitigate the initial budget impact and alleviate existing uncertainties; however, their effective implementation still faces several barriers and will be facilitated by realizing the required organizational changes. Frontiers Media S.A. 2020-12-08 /pmc/articles/PMC7753155/ /pubmed/33363468 http://dx.doi.org/10.3389/fphar.2020.594446 Text en Copyright © 2020 Michelsen, Nachi, Van Dyck, Simoens and Huys http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Michelsen, Sissel
Nachi, Salma
Van Dyck, Walter
Simoens, Steven
Huys, Isabelle
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
title Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
title_full Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
title_fullStr Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
title_full_unstemmed Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
title_short Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
title_sort barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753155/
https://www.ncbi.nlm.nih.gov/pubmed/33363468
http://dx.doi.org/10.3389/fphar.2020.594446
work_keys_str_mv AT michelsensissel barriersandopportunitiesforimplementationofoutcomebasedspreadpaymentsforhighcostoneshotcurativetherapies
AT nachisalma barriersandopportunitiesforimplementationofoutcomebasedspreadpaymentsforhighcostoneshotcurativetherapies
AT vandyckwalter barriersandopportunitiesforimplementationofoutcomebasedspreadpaymentsforhighcostoneshotcurativetherapies
AT simoenssteven barriersandopportunitiesforimplementationofoutcomebasedspreadpaymentsforhighcostoneshotcurativetherapies
AT huysisabelle barriersandopportunitiesforimplementationofoutcomebasedspreadpaymentsforhighcostoneshotcurativetherapies